Hennion & Walsh Asset Management Inc. Sells 56,100 Shares of Mirum Pharmaceuticals, Inc. $MIRM

Hennion & Walsh Asset Management Inc. trimmed its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 59.9% during the second quarter, Holdings Channel.com reports. The institutional investor owned 37,492 shares of the company’s stock after selling 56,100 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Mirum Pharmaceuticals were worth $4,389,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Cullen Frost Bankers Inc. acquired a new stake in Mirum Pharmaceuticals in the fourth quarter valued at $30,000. Eurizon Capital SGR S.p.A. acquired a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth about $32,000. CIBC Private Wealth Group LLC acquired a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth about $32,000. Quantbot Technologies LP bought a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter valued at about $33,000. Finally, Summit Securities Group LLC bought a new stake in shares of Mirum Pharmaceuticals in the 1st quarter valued at about $42,000.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. CLSA set a $146.00 price target on Mirum Pharmaceuticals in a report on Monday, June 15th. Evercore reaffirmed an “outperform” rating and issued a $138.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Citigroup reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Thursday. Wolfe Research assumed coverage on Mirum Pharmaceuticals in a report on Tuesday, May 19th. They set an “outperform” rating and a $145.00 target price on the stock. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $165.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $137.33.

Mirum Pharmaceuticals Stock Performance

Shares of Mirum Pharmaceuticals stock opened at $100.65 on Monday. The firm has a 50-day moving average of $110.33 and a 200-day moving average of $101.86. The stock has a market cap of $6.54 billion, a PE ratio of -6.92 and a beta of 0.52. Mirum Pharmaceuticals, Inc. has a 52-week low of $57.79 and a 52-week high of $130.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.74 and a current ratio of 2.86.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The business had revenue of $176.24 million during the quarter, compared to analyst estimates of $166.33 million. During the same quarter last year, the company posted ($0.12) earnings per share. The company’s revenue was up 37.9% on a year-over-year basis. As a group, sell-side analysts forecast that Mirum Pharmaceuticals, Inc. will post -4.42 EPS for the current year.

Key Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Second-quarter revenue reached $176.24 million, beating the $166.33 million consensus estimate and rising 37.9% year over year. Growth was driven by Livmarli and Mirum’s other bile-acid therapies. Management also raised its 2026 sales outlook, providing a favorable signal about demand and the company’s commercial trajectory. Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts remain broadly constructive despite reducing their targets. TD Cowen lowered its target to $140 and retained a “buy” rating; Citizens JMP cut its target to $137 but maintained “market outperform”; and HC Wainwright reduced its target to $140 while keeping a “buy” rating. These targets imply substantial potential upside from recent trading levels.
• Neutral Sentiment: Mirum reported a quarterly loss of $1.06 per share, wider than the $0.74 consensus loss and the $0.12 loss recorded a year earlier. The loss reflects continued investment in the company’s rare-disease pipeline, but it remains a near-term valuation concern. Mirum’s Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
• Negative Sentiment: Citizens warned that an “unexpected” FDA request for a Phase 3 study clouds Mirum’s near-term outlook. The additional regulatory requirement could delay development or approval plans, increase spending, and weigh on investor sentiment.
• Negative Sentiment: Senior Vice President Jolanda Howe sold 1,840 shares worth approximately $193,734, reducing her direct holdings by 59.1%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which lessens its signaling value, but the sale still adds a modest negative headline.

Insiders Place Their Bets

In other news, CEO Christopher Peetz sold 30,000 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $95.84, for a total value of $2,875,200.00. Following the completion of the sale, the chief executive officer directly owned 194,309 shares in the company, valued at approximately $18,622,574.56. The trade was a 13.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 2,721 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $120.00, for a total value of $326,520.00. Following the completion of the sale, the senior vice president owned 3,114 shares of the company’s stock, valued at approximately $373,680. This trade represents a 46.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 67,155 shares of company stock worth $7,185,662 in the last quarter. Corporate insiders own 8.32% of the company’s stock.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.